Trial Profile
A Real-world study on treatment persistence with Golimumab in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in French clinical practice
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms GO-PRACTICE
- 22 Dec 2021 Results of post-hoc analysis (n=478) assessing persistence and safety of golimumab, together with the evolution of disease activity and patient reported outcomes, in adult patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (axSpA) published in the Clinical and Experimental Rheumatology
- 03 Sep 2020 Results published in the Clinical and Experimental Rheumatology
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism